The advent of transcatheter aortic valve implantation (TAVI) has been rapidly evolving the treatment of the severe aortic stenosis in patients with comorbidities that lead to being high-risk for conventional aortic valve replacement. The patient selection for TAVI is carefully made by a multidisciplinary heart team. An accurate preoperative assessment of the computed tomography angiography and transesophageal echocardiography are necessary for procedural success. In Japan, SAPIEN XT and CoreValve are available, and Lotus Valve is under clinical trial. So far, TAVI is an attractive treatment because the early outcome and the intermediate-term durability are favorable. An answer to a question of whether the indication for TAVI is able to expand to low- or intermediate- risk patients depends on the long-term durability.